Start-up aims to open the door to an entirely new approach to immunotherapy
Pathios Therapeutics raises $25M in first close of Series B financing to advance first-in-class immunotherapy approach into clinic
Biotechnology
SeaBeLife is a biotechnology company developing two families of patented candidate molecules designed to block regulated necrosis – also known as regulated cell death. Our therapeutic solution has demonstrated, in vitro and in multiple in vivo proofs-of-concept, to be able to simultaneously ...
View start-upBiotechnology
At Variant Bio our mission is to leverage the power of human genetic diversity to develop life-saving therapies. We are dedicated to strong ethics, benefit sharing, and improving health around the ...
View start-upBiotechnology
Launched in 2017, Pathios is a drug discovery and development company focused on translating innovative science into new medicines. Pathios was founded by a team of experienced biotech and pharmaceutical industry professionals, entrepreneurs, and clinicians. The company is focused on developing ...
View start-up© 1997-2024 LUMITOS AG, All rights reserved